

# Edward B Garon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/994458/publications.pdf>

Version: 2024-02-01

152  
papers

33,766  
citations

61984

43  
h-index

12272

133  
g-index

154  
all docs

154  
docs citations

154  
times ranked

32512  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies. <i>Clinical Lung Cancer</i> , 2022, 23, 253-263.	2.6	2
2	cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution. <i>Clinical Cancer Research</i> , 2022, 28, 1841-1853.	7.0	4
3	RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability. <i>Drug Safety</i> , 2022, 45, 45-64.	3.2	6
4	Facets of stigma, self-compassion, and health-related adjustment to lung cancer: A longitudinal study. <i>Health Psychology</i> , 2022, 41, 301-310.	1.6	3
5	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
6	Defining comprehensive biomarker-related testing and treatment practices for advanced non-small cell lung cancer: Results of a survey of U.S. oncologists. <i>Cancer Medicine</i> , 2022, 11, 530-538.	2.8	28
7	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma. <i>Journal of Clinical Oncology</i> , 2022, 40, e003956.		16
8	Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. <i>Journal of Clinical Oncology</i> , 2022, 40, 9035-9035.	1.6	0
9	Circulating tumor DNA (ctDNA) mutations associate with response in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib (TALA) and temozolomide (TMZ). <i>Journal of Clinical Oncology</i> , 2022, 40, 8582-8582.	1.6	0
10	Cost of consent document (CD) translation is a potential barrier to consenting limited English-proficient participants (LEPPs) in non-industry-sponsored studies (NISS). <i>Journal of Clinical Oncology</i> , 2022, 40, 6533-6533.	1.6	0
11	RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 90, 137-148.	2.3	4
12	Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study. <i>Supportive Care in Cancer</i> , 2021, 29, 117-125.	2.2	2
13	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 205-215.	1.1	149
14	Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL. <i>Lung Cancer</i> , 2021, 151, 25-29.	2.0	4
15	KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS146-TPS146.	1.6	27
16	Severity of COVID-19 in patients with lung cancer: evidence and challenges. <i>Journal of Clinical Oncology</i> , 2021, 39, e002266.		78
17	Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100150.	1.1	2
18	Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. <i>Lung Cancer</i> , 2021, 155, 53-60.	2.0	8

#	ARTICLE	IF	CITATIONS
19	A Phase Ib Open-Label, Multicenter Study of Inhaled DV281, a TLR9 Agonist, in Combination with Nivolumab in Patients with Advanced or Metastatic Nonâ€“small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4566-4573.	7.0	13
20	Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Nonâ€“Small-Cell Lung Cancer (MYSTIC). <i>Clinical Lung Cancer</i> , 2021, 22, 301-312.e8.	2.6	10
21	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5258-5271.	7.0	23
22	Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis. <i>Nature Communications</i> , 2021, 12, 4172.	12.8	16
23	Abstract 24: Multi-feature ensemble learning on cell-free dna for accurately detecting and locating cancer. <i>Cancer Research</i> , 2021, 81, 24-24.	0.9	3
24	Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1â€“Positive Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1718-1732.	1.1	141
25	Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC. <i>Lung Cancer</i> , 2021, 161, 34-41.	2.0	7
26	Osimertinib plus Ramucirumab: The Best of Both Worlds?. <i>Clinical Cancer Research</i> , 2021, 27, 905-907.	7.0	2
27	390â€“..A global, molecular disease characterization initiative (MDCI) in oncology clinical trials. , 2021, 9, A423-A423.		0
28	457â€“..KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for nonâ€“small cell lung cancer (NSCLC). , 2021, 9, A485-A485.		5
29	Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC. <i>Med</i> , 2021, 2, 1201-1202.	4.4	0
30	364â€“..KRAS mutations in patients with nonsquamous nonâ€“small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status. , 2021, 9, A391-A391.		0
31	What is the current role of immunotherapy in EGFR mutant advanced NSCLC?. <i>Lung Cancer</i> , 2021, , .	2.0	0
32	Detection of EGFR Mutations in cfDNA and CTCs, and Comparison to Tumor Tissue in Non-Small-Cell-Lung-Cancer (NSCLC) Patients. <i>Frontiers in Oncology</i> , 2020, 10, 572895.	2.8	35
33	Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44. <i>Nature Cancer</i> , 2020, 1, 1167-1175.	13.2	22
34	Capmatinib in <i>MET</i> Exon 14â€“Mutated or <i>MET</i>-Amplified Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
35	Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated <i>EGFR</i>-mutated metastatic non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2020, 36, 1667-1675.	1.9	11
36	Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1505-1517.	1.6	710

#	ARTICLE	IF	CITATIONS
37	Medical Treatment of Lung Cancer: Can Immune Cells Predict the Response? A Systematic Review. <i>Frontiers in Immunology</i> , 2020, 11, 1036.	4.8	10
38	Is there hope in improving 5-year overall survival?â€”review of 5-year overall survival data from KEYNOTE-001. <i>Annals of Translational Medicine</i> , 2020, 8, 728-728.	1.7	0
39	Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 387-397.	10.7	119
40	Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Nonâ€”Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, 661.	7.1	446
41	Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy. <i>ESMO Open</i> , 2020, 5, e000567.	4.5	7
42	Capmatinib in patients with high-level <i>MET</i> -amplified advanced nonâ€”small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9509-9509.	1.6	12
43	Capmatinib in patients with <i>MET</i> <sup>ex14</sup> -mutated or high-level <i>MET</i> -amplified advanced nonâ€”small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9520-9520.	1.6	9
44	Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9521-9521.	1.6	17
45	RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9564-9564.	1.6	2
46	Final analysis of KEYNOTE-189: Pemetrexed-platinum chemotherapy (chemo) with or without pembrolizumab (pembro) in patients (pts) with previously untreated metastatic nonsquamous non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9582-9582.	1.6	16
47	Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9619-9619.	1.6	12
48	CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9075-TPS9075.	1.6	6
49	A phase Ib/II study of niraparib plus temozolomide plus atezolizumab versus atezolizumab as maintenance therapy in extensive-stage small cell lung cancer (TRIO-US L-06).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS9084-TPS9084.	1.6	1
50	Pemetrexed (Pem) with pembrolizumab (Pembro) maintenance: A post hoc subgroup safety analysis of KEYNOTE-189.. <i>Journal of Clinical Oncology</i> , 2020, 38, 51-51.	1.6	1
51	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9527-9527.	1.6	1
52	Prevalence of human leukocyte antigen-B27 supertype in the context of positively charged neoepitopes and association with PD-L1 as an immune escape mechanism.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3083-3083.	1.6	0
53	SUN-125 Phase Ib Study of Dual Therapy with an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women with Advanced Non-Small Cell Lung Cancer. <i>Journal of the Endocrine Society</i> , 2020, 4, .	0.2	0
54	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	10.7	418

#	ARTICLE	IF	CITATIONS
55	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e31-e43.	5.6	97
56	Pegilodocakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. Lancet Oncology, The, 2019, 20, 1544-1555.	10.7	86
57	Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story. Journal of Thoracic Oncology, 2019, 14, 160-162.	1.1	0
58	Luminespib plus pemetrexed in patients with non-squamous non-small cell lung cancer. Lung Cancer, 2019, 135, 104-109.	2.0	5
59	Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer. Clinical Cancer Research, 2019, 25, 5061-5068.	7.0	60
60	Lack of clearly defined role for anti-programmed death-(ligand) 1 therapy in epidermal growth factor receptor mutated non-small cell lung cancer. Translational Lung Cancer Research, 2019, 8, 195-197.	2.8	2
61	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC. Journal of Thoracic Oncology, 2019, 14, 793-801.	1.1	50
62	Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis. Future Oncology, 2019, 15, 1481-1491.	2.4	11
63	Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer. Lung Cancer, 2019, 131, 6-13.	2.0	9
64	KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit. Translational Lung Cancer Research, 2019, 8, S403-S406.	2.8	2
65	RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, 9000-9000.	1.6	23
66	KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2019, 37, 9013-9013.	1.6	42
67	Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC.. Journal of Clinical Oncology, 2019, 37, 9048-9048.	1.6	2
68	First-in-human phase 1 study of DS-1062a in patients with advanced solid tumors.. Journal of Clinical Oncology, 2019, 37, 9051-9051.	1.6	12
69	CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS8570-TPS8570.	1.6	6
70	The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9124-TPS9124.	1.6	11
71	Electrostatic human leukocyte antigen-neoantigen interactions and durable benefit in non-small cell lung cancer patients treated with immunotherapy.. Journal of Clinical Oncology, 2019, 37, 2635-2635.	1.6	0
72	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 378, 2078-2092.	27.0	4,701

#	ARTICLE	IF	CITATIONS
73	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. <i>Lung Cancer</i> , 2018, 120, 62-69.	2.0	29
74	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. <i>Cancer Immunology Research</i> , 2018, 6, 288-294.	3.4	70
75	Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer. <i>Scientific Reports</i> , 2018, 8, 2592.	3.3	81
76	Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial. <i>Clinical Lung Cancer</i> , 2018, 19, 270-279.e3.	2.6	8
77	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 576-584.	1.1	62
78	Feasibility and Safety of Intrathoracic Biopsy and Repeat Biopsy for Evaluation of Programmed Cell Death Ligand-1 Expression for Immunotherapy in Non-Small Cell Lung Cancer. <i>Radiology</i> , 2018, 287, 326-332.	7.3	24
79	Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR -Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. <i>Clinical Lung Cancer</i> , 2018, 19, 213-220.e4.	2.6	13
80	Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 77-86.	2.3	18
81	A Prospective Phase 2 Study Evaluating Safety and Efficacy of Combining Stereotactic Body Radiation Therapy With Heat-based Ablation for Centrally Located Lung Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 564-573.	0.8	12
82	Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2018, 19, e19-e28.	2.6	17
83	The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations: The Lung Cancer Mutation Consortium (LCMC2). <i>Clinical Cancer Research</i> , 2018, 24, 1038-1047.	7.0	154
84	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. <i>Science</i> , 2018, 359, 582-587.	12.6	834
85	High-profile studies frequently and repetitively present data on the same patients, particularly in immunotherapy studies. <i>Journal of Thoracic Disease</i> , 2018, 10, S397-S403.	1.4	1
86	A Longitudinal Investigation of Internalized Stigma, Constrained Disclosure, and Quality of Life Across 12 Weeks in Lung Cancer Patients on Active Oncologic Treatment. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1284-1293.	1.1	30
87	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2018, 123, 91-98.	2.0	35
88	Torsades de pointes with pseudo-T wave alternans during rociletinib therapy: A novel manifestation of a rare side effect. <i>Heart Rhythm Case Reports</i> , 2018, 4, 490-493.	0.4	2
89	A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1138-1145.	1.1	426
90	The Italian Nivolumab Expanded Access Program Confirms the Limitations of Single-Agent PD-1 Inhibition in EGFR-Mutant and Never-Smoking Patients with NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1058-1059.	1.1	5

#	ARTICLE	IF	CITATIONS
91	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). , 2018, 6, 75.		188
92	Pembrolizumab Exposureâ€“Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance. Clinical Cancer Research, 2018, 24, 5841-5849.	7.0	160
93	Are lung adenocarcinoma mutations shaping the immune microenvironment?. Translational Cancer Research, 2018, 7, S740-S742.	1.0	2
94	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer. Cell Reports, 2017, 18, 601-610.	6.4	125
95	Phase I Trial of Intratumoral Injection of CCL21 Geneâ€“Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration. Clinical Cancer Research, 2017, 23, 4556-4568.	7.0	149
96	Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer. Lung Cancer, 2017, 112, 126-133.	2.0	11
97	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncology, The, 2017, 18, 895-903.	10.7	872
98	Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). Lung Cancer, 2017, 106, 76-82.	2.0	11
99	Nonâ€“small cell lung cancer clinical trials requiring biopsies with biomarkerâ€“specific results for enrollment provide unique challenges. Cancer, 2017, 123, 4800-4807.	4.1	19
100	Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 96-99.	2.6	10
101	Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study. Translational Lung Cancer Research, 2017, 6, S39-S40.	2.8	5
102	Estimating long-term survival of PD-L1-expressing, previously treated, non-small cell lung cancer patients who received pembrolizumab in KEYNOTE-001 and -010.. Journal of Clinical Oncology, 2017, 35, 77-77.	1.6	6
103	A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer. OncoTargets and Therapy, 2016, Volume 9, 7275-7283.	2.0	49
104	Toward patient-tailored summarization of lung cancer literature. , 2016, 2016, 449-452.		1
105	Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer, 2016, 122, 766-772.	4.1	92
106	Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy. Lung Cancer, 2016, 93, 95-103.	2.0	41
107	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, The, 2016, 387, 1540-1550.	13.7	5,456
108	The Value of PD-L1 Testing in Nonâ€“Small-Cell Lung Cancer. JAMA Oncology, 2016, 2, 571.	7.1	18

#	ARTICLE	IF	CITATIONS
109	The race for combined checkpoint inhibition in NSCLC. <i>Lancet Oncology</i> , The, 2016, 17, 259-260.	10.7	6
110	Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11510-11510.	1.6	20
111	Archival vs new tumor samples for assessing PD-L1 expression in the KEYNOTE-010 study of pembrolizumab (pembro) vs docetaxel (doce) for previously treated advanced NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3030-3030.	1.6	4
112	Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9015-9015.	1.6	10
113	Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9026-9026.	1.6	31
114	Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9104-TPS9104.	1.6	4
115	Effects of FDA drug approvals on a thoracic oncology program's clinical trial enrollment in 2015.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20662-e20662.	1.6	0
116	Patient portal preferences: Perspectives on imaging information. <i>Journal of the Association for Information Science and Technology</i> , 2015, 66, 1606-1615.	2.9	20
117	Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 200-208.	2.6	6
118	Alectinib Induces a Durable (>15 Months) Complete Response in an ALK-Positive Non-Small Cell Lung Cancer Patient Who Progressed on Crizotinib With Diffuse Leptomeningeal Carcinomatosis. <i>Oncologist</i> , 2015, 20, 224-226.	3.7	48
119	Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1700-1709.	27.0	615
120	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
121	Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	12.6	6,756
122	Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2015, 42, S11-S18.	2.2	55
123	Estrogen Receptor-2 and the Insulin-Like Growth Factor Axis as Potential Therapeutic Targets for Triple-Negative Breast Cancer. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 373-390.	0.4	6
124	Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 339-347.	0.4	6
125	Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1998.	7.4	1,386
126	Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 443-452.	2.5	90



#	ARTICLE	IF	CITATIONS
127	Incidental Mediastinal Dose Does Not Explain Low Mediastinal Node Recurrence Rates in Patients With Early-Stage NSCLC Treated With Stereotactic Body Radiotherapy. <i>Clinical Lung Cancer</i> , 2014, 15, 287-293.	2.6	16
128	Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. <i>Lancet</i> , The, 2014, 384, 665-673.	13.7	1,068
129	REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA8006-LBA8006.	1.6	6
130	PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 4349-4357.	1.6	326
131	Uncertainty and psychological adjustment in patients with lung cancer. <i>Psycho-Oncology</i> , 2013, 22, 1396-1401.	2.3	89
132	The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non-“Small Cell Lung Cancer Growth. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 890-900.	4.1	67
133	Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 270-278.	1.1	59
134	Randomized phase III trial of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (Bev) followed by maintenance Pem+Bev (Pem arm) versus paclitaxel (Pac)+Cb+Bev followed by maintenance Bev (Pac arm) in patients (pts) with stage IIIB/IV nonsquamous non-small cell lung cancer (nsNSCLC) (POINTBREAK): African American (AA) subset.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19150-e19150.	1.6	1
135	The role of estrogen, progesterone and aromatase in human non-small-cell lung cancer. <i>Lung Cancer Management</i> , 2012, 1, 259-272.	1.5	27
136	Targeting MEK for the Treatment of Non-“Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2012, 7, S377-S378.	1.1	10
137	Multicenter Trial of EC145 in Advanced, Folate-Receptor Positive Adenocarcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1618-1621.	1.1	32
138	Development of transcriptomic biomarker signature in human saliva to detect lung cancer. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 3341-3350.	5.4	130
139	A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-“Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design. <i>Clinical Lung Cancer</i> , 2012, 13, 505-509.	2.6	37
140	Issues surrounding clinical trial endpoints in solid malignancies with a focus on metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 77, 475-481.	2.0	13
141	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7543-7543.	1.6	28
142	Patient-reported outcomes from POINTBREAK: The randomized, open-label, phase III study of pemetrexed (pem) + carboplatin (cb) + bevacizumab (bev) followed by maintenance pem + bev versus paclitaxel (pac) + cb + bev followed by maintenance bev in patients with stage IIIB or IV nonsquamous non-small cell lung cancer (NS-NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 53-53.	1.6	2
143	<sup>18</sup>F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1684-1689.	5.0	94
144	Progesterone and estrogen receptor expression and activity in human non-small cell lung cancer. <i>Steroids</i> , 2011, 76, 910-20.	1.8	65

#	ARTICLE	IF	CITATIONS
145	Mitotic Inhibitors. Journal of Thoracic Oncology, 2011, 6, S1791-S1792.	1.1	2
146	Poly(ADP-Ribose) Polymerase Inhibitors. Journal of Thoracic Oncology, 2010, 5, S455-S456.	1.1	1
147	Identification of Common Predictive Markers of <i>In vitro</i> Response to the Mek Inhibitor Selumetinib (AZD6244; ARRY-142886) in Human Breast Cancer and Non-Small Cell Lung Cancer Cell Lines. Molecular Cancer Therapeutics, 2010, 9, 1985-1994.	4.1	59
148	Inflammation and lung carcinogenesis: applying findings in prevention and treatment. Expert Review of Anticancer Therapy, 2007, 7, 1405-1421.	2.4	71
149	In vitro and in vivo evaluation and a case report of intense nanosecond pulsed electric field as a local therapy for human malignancies. International Journal of Cancer, 2007, 121, 675-682.	5.1	165
150	Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. Leukemia Research, 2007, 31, 643-651.	0.8	40
151	Utility of Quantum Dots for Labeling and Tracking Leukemic Cell Lines, Human Bone Marrow and CD 34+ Umbilical Cord Blood. Blood, 2005, 106, 1729-1729.	1.4	0
152	Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC. , 0, , .		0